There is increasing evidence that a behavioral treatment approach might be efficacious in the treatment of the emotional aspects of infertility and may lead to increased conception rates. The first 54 women to complete a behavioral treatment program based on the elicitation of the relaxation response showed statistically significant decreases in anxiety, depression, and fatigue as well as increases in vigor. In addition, 34% of these women became pregnant within 6 months of completing the program. These findings established a role for stress reduction in the long-term treatment of infertility. They further suggest that behavioral treatment should be considered for couples with infertility before or in conjunction with reproductive technologies such as intrauterine insemination and gamete intrafallopian transfer.
The mind/body program for infertility: A new behavioral treatment approach for women with infertility
Publication
Fertility and Sterility
Volume 53, Issue 2
Abstract
Web and Email Links
Related Listings
Journal
Journal of Human Stress
Human pupillary dilatation after topical instillation of phenylephrine was assessed in a prospective, randomized, controlled experiment to measure alterations in α-end-organ responsivity after regular elicitation of the relaxation response. Baseline pupillometric measurements were taken in both experimental and control subjects. The experimental subjects then practiced daily a technique that elicited the relaxation response while the control subjects sat quietly for comparable periods […]
Journal
Scientific American
A very readable introduction to the scientific findings in neurology about primarily Buddhist forms of meditation.
Journal
Frontiers in Psychiatry
Background: Obsessive-compulsive disorder (OCD) is often a life-long disorder with high psychosocial impairment. Serotonin reuptake inhibitors (SRIs) are the only FDA approved drugs, and approximately 50% of patients are non-responders when using a criterion of 25% to 35% improvement with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). About 30% are non-responders to combined first-line therapies (SRIs and exposure and response prevention). Previous research (one open, one randomi […]

